Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Osteoporosis associated with primary hyperparathyroidism].

Toshitsugu Sugimoto1

  • 1Division of Endocrinology/Metabolism, Neurology and Hematology/Oncology, Department of Clinical Molecular Medicine, Kobe University Graduate School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 18, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of Urinary Pentosidine Levels With the Risk of Fractures in Patients With Severe Osteoporosis: The Japanese Osteoporosis Intervention Trial-05 (JOINT-05).

JBMR plus·2022
Same author

Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2022
Same author

Relationship Between Changes in Serum Levels of Intact Parathyroid Hormone and Sclerostin After a Single Dose of Zoledronic Acid: Results of a Phase 1 Pharmacokinetic Study.

Calcified tissue international·2021
Same author

Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study.

Calcified tissue international·2021
Same author

Efficacy of once-weekly and twice-weekly injections of teriparatide by patient characteristics: A post hoc analysis of the TWICE study.

Osteoporosis and sarcopenia·2021
Same author

High glucose promotes mineralization via bone morphogenetic protein 4-Smad signals in early stage of osteoblast differentiation.

Diabetology international·2021

Primary hyperparathyroidism (pHPT) causes osteoporosis, particularly in postmenopausal women. Parathyroidectomy (PTX) significantly increases bone mass, offering a cure, while medications provide alternative treatment for mild cases.

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Geriatric Medicine

Context:

  • Primary hyperparathyroidism (pHPT) is a common endocrine disorder.
  • It frequently affects postmenopausal women, contributing to secondary osteoporosis.
  • pHPT predominantly impacts cortical bone density.

Purpose:

  • To review the effects of parathyroidectomy (PTX) and alternative therapies on bone mass in patients with primary hyperparathyroidism.
  • To highlight the benefits of PTX even in asymptomatic hypercalcemia cases.
  • To discuss pharmacological options for managing pHPT in elderly or comorbid patients.

Summary:

  • Parathyroidectomy (PTX) is the definitive treatment for pHPT, leading to significant bone mass increases, even in postmenopausal women.
  • The study notes that pHPT is increasingly recognized as a condition with subtle, asymptomatic hypercalcemia.

Related Experiment Videos

  • Even in asymptomatic cases, PTX can substantially improve bone mineral density.
  • Pharmacological treatments including bisphosphonates, estrogen, and raloxifene are effective in increasing bone mass in elderly pHPT patients.

    • Impact:

    • Parathyroidectomy offers a radical cure for pHPT, improving bone health and potentially reducing fracture risk.
    • The findings support surgical intervention for pHPT, regardless of symptom presentation.
    • Non-surgical options provide valuable therapeutic alternatives for specific patient populations, improving management strategies for osteoporosis in pHPT.